Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), today announced that the Company has taken steps necessary for the commercialization of its early diagnostic tests for breast cancer, Alzheimer’s and Parkinson’s disease, and anticipates revenue from sales and licensing this quarter.
“Power3 Medical is preparing to commercialize its BC SeraPro™, and NuroPro® tests for breast cancer, Alzheimer’s and Parkinson’s. The pre marketing and packaging of the company's early diagnostic test sample kits are complete, and ready for commercialization. Our partners in the foreign markets are primed as the points of release of the tests to the market. Our lab is positioned to run the tests in house with CLIA certification. The initial launch is anticipated for Greece with completion of the clinical validation trials with The University of Thessaly,” stated Dr. Ira L. Goldknopf, President and Chief Scientific Officer of Power3.
“We are delighted to bring these tests into position for commercialization. This is especially timely for the BC SeraPro™ test, with this month’s emphasis on Breast Cancer Awareness,” commented Ms. Helen R. Park, interim CEO of Power3.
About Power3 Medical Products, Inc.
Power3 Medical Products, Inc. (OTCBB:PWRM) (www.Power3Medical.com), is a leading Bio Medical company engaged in the commercialization of cancer and neurodegenerative disease biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.
Power3 Medical Products, Inc., Houston
Interim CEO
Helen R.
Park, M.S., 281-464-1600
Fax: 281-466-1481
hpark@power3medical.com
www.power3medical.com